| Title |
Publication Date |
Price |
Relevance |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£7600 |
100 % |
Cancer Therapeutics Markets
|
May 2008 |
£2075 |
50 % |
Stakeholder Opinions: Cancer Cachexia
Higher profile needed to unlock market potential of neglected syndrome
|
January 2009 |
£2000 |
47.5 % |
Stakeholder Opinions: Ovarian Cancer
Growing importance as secondary indication for targeted therapies
|
July 2006 |
£2195 |
46.5 % |
Commercial Insight: Top 20 Cancer Therapy Brands
Sales of targeted therapies overtake cytotoxics in 2006
|
July 2007 |
£7600 |
46 % |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£5960 |
45.5 % |
Colorectal Cancer: Pipeline/Commercial Insight
Shaping the future dynamics of colorectal cancer management
|
October 2006 |
£8000 |
45.5 % |
Analytical Tool: Prostate Cancer
A Therapeutic & Competitive Insight
|
May 2007 |
£2660 |
44 % |
Avantogen Limited (formerly Australian Cancer Technology Limited) -Company Report
|
February 2008 |
£375 |
39.5 % |
Analytical Tool - Prostate Cancer
A Therapeutic & Competitive Insight
|
January 2009 |
£2660 |
39 % |
Analytical Tool - Colorectal Cancer
|
January 2009 |
£2660 |
39 % |
Analytical Tool - Breast Cancer
|
January 2009 |
£2660 |
39 % |
Therapeutic Radiopharmaceuticals Markets
Sector Snapshot
|
December 2006 |
£305 |
39 % |
Prostate and Breast Cancer
New Treatments & Developmental Progress
|
March 2007 |
£2025 |
38.5 % |
Analytical Tool: Breast Cancer R&D Comprehensive Guide
|
May 2007 |
£2660 |
38 % |
Analytical Tool - Targeted Therapeutics: Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
|
May 2007 |
£2660 |
37.5 % |
Analytical Tool - Cancer Vaccines
|
January 2009 |
£2660 |
37 % |
Analytical Tool: Competitive Outlook on Cancer Vaccines
|
January 2009 |
£2700 |
37 % |
Breast Cancer - Therapeutic And Competitive Insights
|
February 2007 |
£1340 |
35 % |
Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Drug Pipeline Report
|
February 2008 |
£1495 |
35 % |
Breast Cancer
Therapeutic And Competitive Insights
|
February 2007 |
£1340 |
35 % |
GSK's Cervarix
A Future Blockbuster of 2007
|
March 2007 |
£1999 |
34 % |
Analytical Tool - Cancer Therapeutic Antibodies
|
January 2009 |
£3515 |
34 % |
Analytical Tool: The Commercial Success of Cancer Therapeutic Antibodies
|
January 2009 |
£2700 |
34 % |
Pancreatic Cancer Drug Pipeline Report
|
February 2008 |
£1495 |
32.9 % |
Prostate Cancer Drug Pipeline Report
|
February 2008 |
£1495 |
32.55 % |
Ovarian Cancer Drug Pipeline Report
|
February 2008 |
£1495 |
32.2 % |
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer
|
March 2006 |
£2960 |
32 % |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£2960 |
31 % |
Kidney Cancer Drug Pipeline Report
|
February 2008 |
£1495 |
30.8 % |
Liver Cancer Drug Pipeline Report
|
February 2008 |
£995 |
30.8 % |
Melanoma or Skin Cancer Drug Pipeline Report
|
February 2008 |
£1495 |
30.8 % |
Analytical Tool - Analysis of Cancer Immunotherapy
The World Guide
|
May 2007 |
£4245 |
30 % |
Analytical Tool: Analysis of Cancer Immunotherapy
The World Guide
|
May 2007 |
£4245 |
30 % |
Analytical Tool - Competitive Outlook on Anti-Angiogenesis and Vascular Targeting in Oncology
|
January 2009 |
£2700 |
29 % |
Analytical Tool - Protein Kinase Inhibitors in Oncology
|
January 2009 |
£2660 |
28.5 % |
Analytical Tool - Apoptosis in Oncology
|
January 2009 |
£2660 |
28.5 % |
Analytical Tool - Angiogenesis in Oncology
|
January 2009 |
£2660 |
28.5 % |
Analytical Tool: Protein Kinase Inhibitors in Oncology
|
January 2009 |
£2700 |
28.5 % |
Analytical Tool – Hematological Cancers
|
May 2007 |
£5100 |
28.5 % |
Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Therapy Area Pipeline Report
|
March 2009 |
£790 |
28.35 % |
Amgen
Prospects to 2010
|
February 2009 |
£595 |
28 % |
Pricing And Reimbursement Series
NICE Its Impact On The UK Healthcare System And Beyond
|
September 2007 |
£2005 |
28 % |
Targeted Therapies in Oncology
|
May 2007 |
£100 |
27.5 % |
Colorectal Cancer or Colon Cancer Therapy Area Pipeline Report
|
March 2009 |
£790 |
27.3 % |
Milagen, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
27.3 % |
Targeted Therapies in Oncology
|
September 2007 |
£105 |
26 % |
Global Vaccine Market Forecast to 2012
|
June 2006 |
£1220 |
26 % |
Miraculins Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
25.2 % |
U.S. Injectable Drug Pipeline
|
June 2009 |
£3660 |
25.2 % |
Cancer Stem Cells
Emerging Therapeutic, Diagnostic and Market Opportunities (2008)
|
June 2008 |
£1600 |
25.2 % |
Eu Paediatric Medicines Regulation
Boon or Burden?
|
January 2007 |
£1095 |
25 % |
Targeted Diagnostics & Therapeutics, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
24.85 % |
Kidney Cancer Therapy Area Pipeline Report
|
March 2009 |
£790 |
24.5 % |
Prostate Cancer Therapy Area Pipeline Report
|
March 2009 |
£790 |
24.5 % |
Bladder Cancer Therapy Area Pipeline Report
|
March 2009 |
£790 |
24.5 % |
Pancreatic Cancer Therapy Area Pipeline Report
|
March 2009 |
£790 |
24.5 % |
Ovarian Cancer Therapy Area Pipeline Report
|
March 2009 |
£790 |
24.5 % |
Target Discovery, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
24.5 % |
Liver Cancer Therapy Area Pipeline Report
|
March 2009 |
£790 |
24.5 % |
Orion Genomics Product Pipeline Analysis
|
August 2008 |
£460 |
24.5 % |
Gastrointestinal (Stomach) Cancer Therapy Area Pipeline Report
|
March 2009 |
£790 |
24.15 % |
Breast Cancer Therapy Area Pipeline Report
|
March 2009 |
£790 |
24.15 % |
Melanoma or Skin Cancer Therapy Area Pipeline Report
|
March 2009 |
£790 |
24.15 % |
Pulmonary Imaging: Contributions to Key Clinical Questions
|
June 2007 |
£140 |
24 % |
Novo Nordisk Pharmaceutical Company Intelligence Report
Prospects to 2010
|
May 2007 |
£595 |
24 % |
Head and Neck Cancer Therapy Area Pipeline Report
|
March 2009 |
£790 |
23.8 % |
InterGenetics Incorporated Product Pipeline Analysis
|
August 2008 |
£460 |
23.8 % |
Who's Developing What in New Cancer Drugs 2006?
|
November 2007 |
£495 |
23.45 % |
Psoriasis and Psoriatic Arthritis
A Strategic Analysis of the Market in the United States
|
September 2006 |
£2135 |
22.5 % |
Wyeth Prospects to 2010
Performance, Products, Pipeline and Potential
|
July 2007 |
£595 |
22.5 % |
DiaGenic ASA Product Pipeline Analysis
|
August 2008 |
£460 |
22.05 % |
Onconome, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
21.7 % |
The Cancer Market Outlook to 2012
|
January 2008 |
£1995 |
21.7 % |
Exiqon AS Product Pipeline Analysis
|
May 2008 |
£460 |
21.7 % |
Alzheimer's Disease:Markets, Pipeline and Opportunities 2009
|
April 2009 |
£1855 |
21.5 % |
Glycominds Ltd. Product Pipeline Analysis
|
August 2008 |
£460 |
21.35 % |
Pipeline Insight: Therapeutic Cancer Vaccines
A turbulent path from bench to bedside
|
December 2006 |
£6000 |
21.35 % |
Correlogic Systems, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
21.35 % |
Innovations in Cancer
Novel Therapeutics, New Diagnostics and Future R&D Strategies
|
February 2007 |
£1495 |
21.35 % |
Analytical Tool - Melanoma
|
January 2009 |
£2660 |
21 % |
U.S. Stem Cell Market - Current Development
|
September 2008 |
£2375 |
21 % |
A&G Pharmaceutical, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
21 % |
Analytical Tool - Targeted Therapeutics: Melanoma
|
July 2007 |
£2660 |
21 % |
MicroRNA Research Tools 2008
|
January 2008 |
£1540 |
21 % |
DNAPrint Genomics, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
20.65 % |
Chronic Pain
|
June 2007 |
£74.99 |
20.65 % |
Epigenetics and MicroRNA Diagnostics/Therapeutics 2008
|
May 2008 |
£2350 |
20.65 % |
GUIDED THERAPEUTICS, INC. Product Pipeline Analysis
|
August 2008 |
£460 |
20.65 % |
Gene Express, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
20.65 % |
Epigenomics AG Product Pipeline Analysis
|
August 2008 |
£460 |
20.3 % |
bioMerieux S.A. Product Pipeline Analysis
|
May 2008 |
£460 |
20.3 % |
Biogen Idec
Pipeline Products Performance Potential
|
March 2008 |
£595 |
20 % |
Stakeholder Opinions: Head and Neck Cancer
Innovatives to Change the Face of Treatment
|
November 2007 |
£2005 |
19.95 % |
GRANT Life Sciences, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
19.6 % |
Biogen Idec: Pipeline - Products - Performance - Potential
|
January 2009 |
£595 |
19.5 % |
Stakeholder Opinions: Gastric Cancer
Targeted Therapies Home In On a Neglected Tumor Type
|
March 2006 |
£2195 |
19.25 % |
Qiagen N.V. Product Pipeline Analysis
|
August 2008 |
£460 |
19.25 % |
Hereditary Breast Cancer
|
September 2007 |
£105 |
18.9 % |
Epinex Diagnostics Incorporated Product Pipeline Analysis
|
August 2008 |
£460 |
18.55 % |
Stakeholder Opinions: Pancreatic Cancer - Gemzar dominance will continue among high levels of persistent unmet needs
Healthcare
|
March 2009 |
£2000 |
18.55 % |
SpectRx, Inc. Product Pipeline Analysis
|
May 2008 |
£460 |
18.2 % |
AdnaGen AG Product Pipeline Analysis
|
August 2008 |
£460 |
18.2 % |
Competitive Outlook on Apoptosis in Oncology
|
December 2006 |
£1670 |
17.85 % |
Hai Kang Life Corporation Limited Product Pipeline Analysis
|
August 2008 |
£460 |
17.85 % |
US Oncology, Inc. - Strategic Analysis Review
|
June 2009 |
£76 |
17.85 % |
Poniard Pharmaceuticals Inc
Premium Company Profile
|
April 2008 |
£265 |
17.5 % |
Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis
3rd Edition
|
November 2008 |
£2435 |
17.15 % |
Roche: Prospects to 2010
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
17 % |
Peripheral Neuropathy and Neuropathic Pain, 2008
Current, Pipeline And Emerging Drugs For The Treatment Of Peripheral Neuropathy And Neuropathic Pain
|
January 2008 |
£1499 |
16.8 % |
Perceptronix Medical Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
16.8 % |
CytoCore, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
16.8 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1680 |
16.45 % |
World market for cancer vaccines 2007-2012
|
January 2007 |
£1999 |
16.45 % |
Lymphoma
A Therapeutic & Competitive Insight
|
May 2006 |
£1670 |
16.45 % |
Aethlon Medical, Inc. Healthcare - Medical Equipment SWOT Report
|
May 2008 |
£76 |
16.45 % |
Cancer Market Trends 2008 - 2012
Key market forecasts and growth opportunities
|
January 2009 |
£1100 |
16.45 % |
Stakeholder Opinions: Bladder Cancer
New drugs needed to challenge ineffective 20 year old drugs
|
November 2008 |
£2000 |
16.1 % |
Pipeline Insight: Breast Cancer
Recent approvals increase pressure on pipeline candidates
|
April 2008 |
£6000 |
16.1 % |
Outlook for RNAi, 2007
siRNA and miRNA in biology, diagnostics and therapeutics
|
June 2007 |
£1495 |
16 % |
Takeda
Pipeline, Products,Performance,Potential
|
October 2008 |
£595 |
16 % |
Antiageing and Life Enhancement Pharmacotherapeutics
|
January 2006 |
£4600 |
16 % |
BSD Medical Corporation Product Pipeline Analysis
|
August 2008 |
£460 |
15.75 % |
Cancer Therapeutics
Market Insight and R&D Pipeline Analysis
|
August 2008 |
£2135 |
15.75 % |
World Vaccines Market 2008-2013
Future Forecast, Critical Trends and Developments
|
April 2009 |
£509 |
15.5 % |
Chinese Markets for Cancer Treatment Drugs
|
September 2005 |
£2440 |
15.4 % |
Global Pipeline Review & Analysis of Hematological Malignancies
|
March 2007 |
£2025 |
15.4 % |
Therapeutic Peptides in Oncology
Favorable Conditions But Where to Commercialize?
|
May 2009 |
£2960 |
15.4 % |
Gen-Probe Incorporated Product Pipeline Analysis
|
August 2008 |
£460 |
15.4 % |
Emerging Cancer Vaccine Market, The
2nd Edition
|
November 2006 |
£2135 |
15.05 % |
Pharmaceutical Outsourcing Opportunities Post Launch
Contract Manufacturing, and Sales and Marketing,2nd Edition
|
September 2006 |
£2380 |
15.05 % |
The Impact of the Phase III Pipeline
Future Projections and Market Disruptions
|
March 2006 |
£2135 |
15.05 % |
World Market for Prescription Generic Drugs; The
5th Edition
|
April 2006 |
£2135 |
15.05 % |
Medical and Biological Sensors and Sensor Systems
Markets, Applications, and Competitors Worldwide, 2nd Edition
|
May 2006 |
£2135 |
15.05 % |
Daiichi Sankyo: Pipeline, Products, Performance, Potential
|
June 2008 |
£595 |
15.05 % |
China Sky One Medical, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
15.05 % |
Digene Corporation Product Pipeline Analysis
|
May 2008 |
£460 |
15.05 % |
Daiichi Sankyo
Pipeline, Products, Performance, Potential
|
October 2008 |
£595 |
15.05 % |
China Medical Technologies, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
15.05 % |
World Market for Pain Management Drugs and Devices
2nd Edition
|
December 2006 |
£2135 |
15.05 % |
The Worldwide Market for Cancer Diagnostics
3rd Edition
|
March 2008 |
£2435 |
15.05 % |
Introgen Therapeutics Inc
Premium Company Profile
|
April 2008 |
£265 |
15.05 % |
Global Market for Adjunctive Therapies in Cancer, The
2nd Edition
|
April 2006 |
£2135 |
15.05 % |
Vaccines Market Insight
Products, Pipelines & Market Outlook
|
January 2007 |
£1095 |
15.05 % |
Financial Markets Research: Spectrum Pharmaceuticals' Oral Satraplatin
Oral therapy to take share in second-line hormone-refractory prostate cancer market
|
September 2006 |
£2195 |
15.05 % |
World Market for Prescription Gastrointestinal Drugs, The
|
July 2006 |
£2135 |
15.05 % |
World Market for Psychotherapeutic Drugs, The
|
January 2007 |
£2135 |
15.05 % |
World Market for Prescription Orthopedic Drugs, The
|
October 2006 |
£2135 |
15.05 % |
World Market for Prescription Respiratory Drugs, The
|
October 2006 |
£2135 |
15.05 % |
U.S. and Worldwide Monoclonal Antibody Medicine
Current Status and Future Trends
|
August 2008 |
£670 |
14.7 % |
Stakeholder Opinions: Bone Metastases
Impending Patent Expiries May Help Make or Break Newer Agents
|
March 2008 |
£2005 |
14.7 % |
Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments
World Market
|
May 2007 |
£1215 |
14.7 % |
Stakeholder Insight: Pricing and Reimbursement in Oncology
Do payers believe oncology drugs offer good value?
|
December 2006 |
£6000 |
14.5 % |
Emerging Pharmaceutical Markets Globally
|
April 2008 |
£915 |
14.5 % |
An Overview of the South African Healthcare Industry
|
December 2008 |
£4575 |
14.5 % |
Immunotherapy of Cancer
|
March 2007 |
£2960 |
14.35 % |
Competitive Outlook on Non-Antibody Based Cancer Vaccines
|
August 2006 |
£1670 |
14.35 % |
Cancer Drug Resistance
2008
|
September 2008 |
£1675 |
14.35 % |
Cancer Personalized Medicine 2008
|
July 2008 |
£2425 |
14 % |
Pipeline Insight: Breakthrough Pain
Fast-acting players will capture majority market share
|
November 2006 |
£6000 |
14 % |
Epigenetics
Technologies, Applications, and the Commercial Landscape
|
February 2008 |
£685 |
14 % |
Commercial Insight Top 20 Cancer Therapeutics
|
July 2006 |
£8695 |
14 % |
Cell Culture
The World Market for Media, Sera, and Reagents
|
January 2007 |
£2380 |
14 % |
Biomarkers: A Market Briefing
A Market Briefing
|
January 2007 |
£1215 |
14 % |
SpectraScience, Inc. Healthcare
Medical Equipment SWOT Report
|
July 2008 |
£76 |
13.65 % |
Micromet, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
13.65 % |
Elekta AB Healthcare - Medical Equipment SWOT Report
|
August 2008 |
£76 |
13.65 % |
Currently Druggable in Colorectal Cancer
A Drug Target Competitive Analysis
|
December 2008 |
£1670 |
13.65 % |
Chinese Markets for Ovarian Cancer Treatment Drugs
|
April 2009 |
£2755 |
13.65 % |
Cancer Therapies: Technologies and Global Markets
|
January 2008 |
£2960 |
13.65 % |
Commercial and Pipeline Insight: Opioids
Short Acting and Anti-Abuse Technologies Set to Fragment and Grow The Market
|
March 2008 |
£7600 |
13.65 % |
Stakeholder Opinions: Gynecological Cancers
Niche opportunities in advanced disease
|
December 2006 |
£2005 |
13.65 % |
Indian Healthcare - New Avenues for Growth
|
October 2008 |
£490 |
13.5 % |
Strategic Outlook on Protein Kinase Inhibitors in Oncology
|
February 2006 |
£1670 |
13.3 % |
MedImmune, Inc. - Strategic Analysis Review
|
June 2009 |
£76 |
13.3 % |
Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
|
October 2006 |
£1670 |
13.3 % |
Commercial Insight: Antihormonal Therapy Cancer Brands
Careful Lifecycle Management Needed to Preserve Brand Dominance
|
August 2008 |
£7600 |
13.3 % |
Helix BioPharma Corp. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
13.3 % |
EpiCept Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
12.95 % |
Wellstar International, Inc. Healthcare
Medical Equipment SWOT Report
|
July 2008 |
£76 |
12.95 % |
TomoTherapy Incorporated Healthcare
Medical Equipment SWOT Report
|
July 2008 |
£76 |
12.95 % |
Accuray Incorporated Healthcare - Medical Equipment SWOT Report
|
August 2008 |
£76 |
12.95 % |
Israel Surgical Equipment Investment Opportunities
Analysis and Forecasts to 2015
|
May 2009 |
£1525 |
12.95 % |
Currently Druggable in Prostate Cancer
A Drug Target Competitive Analysis
|
September 2008 |
£1670 |
12.95 % |
Currently Druggable in Breast Cancer
A Drug Target Competitive Analysis
|
August 2008 |
£1670 |
12.95 % |
Siemens Medical Solutions Product Pipeline Analysis
|
August 2008 |
£460 |
12.6 % |
Positron Emission Tomography Markets
|
December 2007 |
£1220 |
12.6 % |
IRIS International, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
12.6 % |
Elekta AB
Strategic Analysis Profile
|
February 2008 |
£34 |
12.6 % |
Convergence of Biomarkers and Diagnostics, The
Therapy Area Analyses, Key Products and Future Trends
|
April 2008 |
£1995 |
12.6 % |
Fresenius SE Healthcare - Medical Equipment SWOT Report
|
August 2008 |
£76 |
12.6 % |
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology
|
December 2006 |
£2960 |
12.6 % |
Gene Therapy
Technologies, Markets and Companies
|
May 2009 |
£2440 |
12.5 % |
FUJIFILM Medical Systems USA, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
12.25 % |
Siemens AG Product Pipeline Analysis
|
August 2008 |
£460 |
12.25 % |
Canadian Pharmaceutical Market Outlook to 2013
olicy environment, market structure, pipeline analysis, growth opportunities
|
March 2009 |
£2025 |
12.25 % |
Oncology Market Leaders
Analyses and Outlook, Market Report 2008 - 2023
|
October 2008 |
£1499 |
12.25 % |
Commercial Insight: Targeted Therapy Cancer Brands
High Growth Market Will See Eight New Blockbusters by 2017
|
July 2008 |
£7600 |
12.25 % |
India in Vitro Diagnostics Investment Opportunities
Analysis and Forecasts to 2015
|
April 2009 |
£1525 |
12.25 % |
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
|
November 2007 |
£1680 |
12.25 % |
The Medical Device Market
Denmark
|
May 2008 |
£595 |
12.25 % |
World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The
|
May 2009 |
£2435 |
12.25 % |
Commercial and Pipeline Insight: Psoriasis
Anti-TNF's lead another indication
|
December 2006 |
£8000 |
12.25 % |
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
|
December 2006 |
£4440 |
12.25 % |
Bioniche Life Sciences - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
12.25 % |
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma
Limited R&D activity provides opportunity for early-phase pipeline drugs
|
March 2007 |
£2005 |
12.25 % |
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
|
May 2006 |
£2960 |
11.9 % |
Innovations in Diagnostics
|
September 2006 |
£1495 |
11.9 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
|
June 2007 |
£2365 |
11.9 % |
The Medical Device Market: Cuba
|
March 2008 |
£595 |
11.9 % |
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
|
August 2006 |
£2960 |
11.9 % |
The Medical Device Market
Taiwan
|
May 2008 |
£595 |
11.9 % |
The Medical Device Market
Taiwan
|
May 2008 |
£595 |
11.9 % |
Monoclonal Antibodies in Cancer Therapy 2009-2024
|
May 2009 |
£1499 |
11.9 % |
Asia-Pacific Surgical Equipment Investment Opportunities
Analysis and Forecasts to 2015
|
May 2009 |
£1525 |
11.9 % |
The Medical Device Market: New Zealand
|
April 2007 |
£595 |
11.55 % |
Flexible Endoscope Pipeline Technology and Market Forecasts to 2015
|
May 2009 |
£1220 |
11.55 % |
The Medical Device Market: Taiwan
|
March 2007 |
£595 |
11.55 % |
The Future of Biobanks
Regulation, ethics, investment and the humanization of drug discovery
|
March 2009 |
£2025 |
11.55 % |
The Medical Device Market: Denmark
|
April 2007 |
£595 |
11.55 % |
Cancer Antibodies
Competitive Positioning for Success
|
June 2008 |
£1670 |
11.55 % |
The Pharmaceutical Market: Norway
|
March 2006 |
£595 |
11.55 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
|
July 2007 |
£2365 |
11.55 % |
The Medical Device Market
Czech Republic
|
May 2008 |
£595 |
11.55 % |
Immunomodulators
Therapeutic Needs, Pipelines & Prospects
|
August 2007 |
£1495 |
11.55 % |
ImmunoGen, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
11.55 % |
Watson
Pharmavitae Generics Profile
|
September 2007 |
£2005 |
11.55 % |
F. Hoffmann-La Roche Ltd. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
11.55 % |
Companion Diagnostics Markets
(A Realistic Assessment of the Opportunities, Challenges, Key Players and Important Trends in Personalized Medicine)
|
June 2008 |
£1825 |
11.2 % |
Women's Health: Worldwide Prescription Drug Markets, 4th Edition
|
February 2009 |
£1825 |
11.2 % |
Gen-Probe Incorporated Healthcare - Medical Equipment SWOT Report
|
August 2008 |
£76 |
11.2 % |
Pharmaceutical Markets in India
|
April 2004 |
£790 |
11.2 % |
Pharmacodiagnostics and Personalized Medicine 2009
(Markets, Challenges, Forecasts and Key Players)
|
April 2004 |
£2135 |
11.2 % |
Melanoma - Targeted Therapeutics
|
July 2007 |
£1340 |
11.2 % |
F. Hoffmann-La Roche Ltd.
Strategic Analysis Profile
|
February 2008 |
£480 |
11.2 % |
Dynamic Antibody Industry
|
August 2005 |
£2960 |
11.2 % |
Australia Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2015
|
March 2009 |
£1525 |
11.2 % |
Promising Drug Discovery Tools in Antifungal & Status on Emerging Novel Targets
|
August 2004 |
£425 |
11 % |
Generic Drug Market in Canada
|
February 2008 |
£855 |
11 % |
Vaccines: The World Market
|
February 2007 |
£2435 |
10.85 % |
The Pharmaceutical Market: Latvia
|
November 2006 |
£595 |
10.85 % |
Chinese Markets for Vaccines
|
March 2006 |
£1985 |
10.85 % |
The Pharmaceutical Market: New Zealand
|
April 2007 |
£595 |
10.85 % |
Myriad Genetics, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
10.85 % |
Vaccines
The World Market
|
February 2007 |
£2435 |
10.85 % |
Biotechnology and Biopharmaceuticals
Transforming Proteins and Genes into Drugs
|
July 2003 |
£55.95 |
10.85 % |
China in Vitro Diagnostics Investment Opportunities
Analysis and Forecasts to 2015
|
April 2009 |
£1525 |
10.85 % |
The Medical Device Market: Latvia
|
November 2006 |
£595 |
10.85 % |
Advaxis, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
10.85 % |
GenVec, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
10.85 % |
SenoRx, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
10.85 % |
Germany Diagnostic Imaging Investment Opportunities, Analysis and Forecasts to 2015
|
March 2009 |
£1525 |
10.85 % |
Alfacell Corporation - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
10.85 % |
The Pharmaceutical Market
Czech Republic
|
May 2008 |
£595 |
10.85 % |
Innovation in Drug Delivery
The future of nanotechnology and non-invasive protein delivery
|
November 2006 |
£1495 |
10.85 % |
Cancer Vaccine Developments to 2011
|
September 2007 |
£1296 |
10.5 % |
F. Hoffmann-La Roche Ltd. Healthcare - Medical Equipment SWOT Report
|
August 2008 |
£76 |
10.5 % |
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
|
October 2006 |
£2960 |
10.5 % |
Pipeline Insight: Non-Small Cell Lung Cancer
Pipeline set to offer only modest improvements
|
April 2008 |
£6000 |
10.5 % |
Clarient, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
10.5 % |
Amgen Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
10.5 % |
GammaCan International Inc - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
10.5 % |
Neoprobe Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
10.5 % |
Stakeholder Insight: Chronic Leukemias
Is there room left for improvement?
|
November 2008 |
£8000 |
10.5 % |
Pharmaceutical Markets in Brazil, Russia, India and China (Bric Nations)
|
July 2008 |
£1075 |
10.5 % |
Monoclonal Antibodies 2007
Competitive Landscape & Pipeline Insight
|
January 2007 |
£1375 |
10.5 % |
Stakeholder Opinions: Primary Brain Cancer
Temozolomide Turns Heads
|
July 2007 |
£2005 |
10.5 % |
Stakeholder Opinions: Hepatocellular Carcinoma
Opportune indication for novel therapies
|
June 2007 |
£3800 |
10.5 % |
Bionovo, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
10.15 % |
New Therapeutics and Diagnostics for Women’s Disorders
|
May 2005 |
£2960 |
10.15 % |
BioCryst Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
10.15 % |
Callisto Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
10.15 % |
GW Pharmaceuticals plc - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
10.15 % |
GTx, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
10.15 % |
Celldex Therapeutics, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
10.15 % |
Elekta AB Medical Equipment Company Share Analysis
|
September 2008 |
£610 |
10.15 % |
Hematological Cancers - A Therapeutic & Competitive Insight
|
October 2006 |
£2530 |
10.15 % |
Arana Therapeutics Limited - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
10.15 % |
Nippon Kayaku Co., Ltd. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
10.15 % |
Analytical Tool - Hematological Cancers
|
May 2007 |
£5100 |
10.15 % |
Commercial Insight: Cytotoxic Therapy Cancer Brands
Looming Patent Expiries Limit Market Growth
|
July 2008 |
£7600 |
10.15 % |
Cytology and HPV Testing World Markets
|
July 2008 |
£2075 |
10.15 % |
Active Biotech AB - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
10.15 % |
How to React to Parallel Trade
|
January 2007 |
£1095 |
10 % |
Companion Animal Health Products: New edition
|
January 2006 |
£795 |
10 % |
Pipeline/Commercial Insight: Supportive Care in Oncology
Significant growth opportunities exist in new supportive care indications
|
June 2007 |
£7600 |
9.8 % |
Idera Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
9.8 % |
Genta Incorporated - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
9.8 % |
The Pharmaceutical Market: Denmark
|
April 2007 |
£595 |
9.8 % |
Celgene Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
9.8 % |
Pipeline Insight: Molecular Targeted Cancer Therapies
More pipeline activity, less product differentiation
|
November 2008 |
£8000 |
9.8 % |
Cancer Cell Therapy Markets
|
March 2008 |
£2075 |
9.8 % |
Genentech, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
9.8 % |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£4245 |
9.8 % |
Scrip Yearbook 2007
23rd Edition (2 Volumes)
|
January 2006 |
£895 |
9.8 % |
In Vitro Diagnostics to 2009
Demand and Sales Forecasts, Market Share, Market Size, Market Leaders
|
April 2007 |
£2745 |
9.8 % |
GPC Biotech AG - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
9.8 % |
Digene Corporation Medical Equipment Company Share Analysis
|
July 2008 |
£610 |
9.8 % |
Comprehensive Analysis of R&D and Commercialization
for Related Biotechnologies from Non-Biotechnology/Non-Pharmaceutical Companies 100
|
February 2007 |
£670 |
9.5 % |
The Pharmaceutical Market: Hong Kong
|
July 2006 |
£595 |
9.45 % |
Commercial and Pipeline Perspectives: Obesity
Lack of Reimbursement Limits Market Potential
|
December 2006 |
£6000 |
9.45 % |
Cancer Therapeutics: The Worldwide Market
The Worldwide Market , 2nd Editon
|
February 2007 |
£2435 |
9.45 % |
The Epigenetics Healthcare R&D, Products and Commercial Implications
Tools, Technologies, Equipment, Opportunities & Emerging WW Market Outlook
|
January 2009 |
£1025 |
9.45 % |
The Global Pain Market 2008-2023
|
November 2008 |
£1499 |
9.45 % |
OSI Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
9.45 % |
Leukemia
A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking
|
April 2009 |
£1670 |
9.45 % |
World Market for Gastrointestinal Endoscopy Equipment
|
January 2009 |
£2135 |
9.45 % |
Chinese Markets for Pharmaceuticals
|
August 2005 |
£2440 |
9.45 % |
Siemens Medical Solutions Healthcare - Medical Equipment SWOT Report
|
August 2008 |
£76 |
9.45 % |
Guide to Valuation of Pharmaceutical Licensing Deals
|
February 2009 |
£1500 |
9.1 % |
The Medical Device Market: Turkey
|
December 2006 |
£595 |
9.1 % |
The Pharmaceutical Market: Saudi Arabia
|
August 2007 |
£595 |
9.1 % |
Forecast of the Key Pipeline Devices to Impact the Medical Equipment Market by 2012
|
December 2008 |
£2135 |
9.1 % |
Protease Inhibitors
Innovation Drives Drug Pipeline
|
February 2009 |
£2290 |
9.1 % |
The Pharmaceutical Market: Taiwan
|
March 2007 |
£595 |
9.1 % |
5th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production
A Study of Biotherapeutic Developers and Contract Manufacturing Organizations, 2007
|
April 2008 |
£970 |
9 % |
Pipeline Insight: Benign Prostatic Hyperplasia - Novel therapeutics and reformulations will drive market growth
|
April 2009 |
£6000 |
8.75 % |
Pipeline And Commercial Insight
Pediatric And Adolescent Vaccines
|
July 2007 |
£8000 |
8.75 % |
Approaches to Reducing Phase II Attrition
|
May 2009 |
£2290 |
8.75 % |
United Sates Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2015
|
March 2009 |
£1525 |
8.75 % |
Obesity Drug Markets in the US and EU
Analysis of product pipelines and the competitive environment
|
July 2008 |
£1995 |
8.75 % |
Canada in Vitro Diagnostics Investment Opportunities
Analysis and Forecasts to 2015
|
April 2009 |
£1525 |
8.75 % |
Lpath, Inc. - Strategic Analysis Review
|
June 2009 |
£76 |
8.75 % |
The Global Pain Therapeutics Market
Market Analysis, R&D Pipelines and Competitive Landscape
|
October 2007 |
£1830 |
8.75 % |
Women's Health
Worldwide Prescription Drug Markets
|
August 2006 |
£2380 |
8.75 % |
High-Growth Diagnostic Testing Markets
|
November 2008 |
£2075 |
8.75 % |
Women's Health
Worldwide Prescription Drug Markets
|
August 2006 |
£1200 |
8.75 % |
Accuray Incorporated Medical Equipment Company Share Analysis
|
September 2008 |
£610 |
8.75 % |
HighGrowth Diagnostic Markets
|
November 2008 |
£2075 |
8.75 % |
UK Pharmaceuticals & Healthcare
|
September 2006 |
£395 |
8.5 % |
Genomics World Markets
|
May 2008 |
£2075 |
8.4 % |
Therapeutic Monoclonal Antibodies Report 2008-2023
|
July 2008 |
£1499 |
8.4 % |
Emerging Opportunities with Cannabinoids
|
September 2008 |
£795 |
8.4 % |
Drug-Device Combinations
|
June 2005 |
£2960 |
8.4 % |
Stakeholder Insight: Non-Small Cell Lung Cancer
The need for greater product differentiation in an increasingly crowded market
|
November 2006 |
£8000 |
8.4 % |
Epigenomics
Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics
|
March 2007 |
£2960 |
8.4 % |
The Pharmaceutical Market: Cuba
|
February 2007 |
£595 |
8.4 % |
RNA Interference Markets
|
December 2008 |
£2075 |
8.4 % |
The Pharmaceutical Market
Taiwan
|
May 2008 |
£595 |
8.4 % |
Akzo Nobel
Prospects to 2010
|
October 2006 |
£795 |
8.4 % |
Global Image Dermatology Drug Market, 2005-2012, The
High-Growth Opportunities in Aesthetic Medicine
|
November 2005 |
£1900 |
8.4 % |
The Pharmaceutical Market
Taiwan
|
May 2008 |
£595 |
8.4 % |
Commercial and Pipeline Insight: HRT for Menopausal Symptoms
A new class restores an old market
|
April 2008 |
£8000 |
8.4 % |
Bausch & Lomb Incorporated Product Pipeline Analysis
|
August 2008 |
£460 |
8.4 % |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
|
October 2006 |
£8000 |
8.05 % |
Commercial and Pipeline Insight: Inflammatory Bowel Disease
Competition Increases for the Biologics
|
November 2006 |
£6000 |
8.05 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
8.05 % |
Companion Diagnostics in Personalized Medicine and Cancer Therapy
|
April 2008 |
£2075 |
8.05 % |
GE Healthcare Product Pipeline Analysis
|
May 2008 |
£460 |
8.05 % |
Currently Druggable in Melanoma
A Drug Target Competitive Analysis
|
October 2008 |
£1670 |
8.05 % |
AMD Market Outlook to 2012
|
March 2007 |
£1299 |
8.05 % |
Indian Medical Market Report
2005
|
May 2005 |
£675 |
8.05 % |
Molecular Diagnostics
A Dynamic and Rapidly Broadening Market Overview
|
January 2009 |
£2290 |
8.05 % |
Medical Imaging Markets, Volume I
Radiography (X-Ray, Digital X-Ray, Fluoroscopy, Mammography, and Ct Markets)
|
February 2009 |
£2135 |
8.05 % |
Molecular Diagnostics
Major World Markets
|
February 2007 |
£2435 |
8.05 % |
Partneringreview 2006 – Financings
Volume 3
|
February 2006 |
£1395 |
8 % |
Gene Expression Profiling Markets
|
January 2008 |
£2435 |
7.7 % |
Molecular Diagnostics 2007
Technologies, Companies, Products, Applications and Worldwide Outlook
|
May 2007 |
£1540 |
7.7 % |
Cancer Diagnostic Testing World Markets
|
April 2008 |
£2075 |
7.7 % |
Pediatric Drugs: the Worldwide Market
3rd Edition
|
December 2007 |
£2435 |
7.7 % |
Japanese Pharmaceutical Market, 2006-2011
|
January 2006 |
£1499 |
7.7 % |
The World Market for Gynaecology
2007-2017
|
September 2007 |
£3200 |
7.7 % |
Clinical Nutrition Products
World Markets, 3rd Edition
|
February 2009 |
£2315 |
7.7 % |
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
|
April 2008 |
£2075 |
7.7 % |
What's Hot in Cancer Drug R&D?
|
July 2006 |
£295 |
7.7 % |
Commercial Insight: Pain Market Overview
Non-Traditional Analgesics and Opioid Reformulations to Sustain Sector Growth
|
October 2008 |
£8000 |
7.7 % |
Rimonabant: The first of the Cannabinoid blockbusters
|
June 2007 |
£1499 |
7.7 % |
Partneringreview 2006
|
February 2006 |
£2195 |
7.5 % |
Partneringreview 2006 – Industry Sector
Volume 6
|
February 2006 |
£1395 |
7.5 % |
Rheumatoid Arthritis: Emerging drug discovery targets
And therapeutic candidates
|
October 2003 |
£375 |
7.5 % |
Partneringreview 2006 – Stage of Development
Volume 4
|
February 2006 |
£1395 |
7.5 % |
Stakeholder Insight: Major Depressive Disorder
Duloxetine - Fulfilling An Unmet Need?
|
March 2006 |
£8695 |
7.35 % |
In-Vitro Diagnostics
US Industry Study with Forecasts for 2013 & 2018
|
March 2009 |
£2930 |
7.35 % |
Exelixis, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7.35 % |
Preclinical Cancer Therapeutics 2007
Decoding Next Generation Drug Targets for Market Success
|
December 2006 |
£1600 |
7.35 % |
Medarex, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7.35 % |
Medivation, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7.35 % |
Allos Therapeutics, Inc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7.35 % |
Drug Delivery Technologies: Players, products & prospects to 2015
|
November 2007 |
£1795 |
7.35 % |
PDL BioPharma, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7.35 % |
ARQULE, INC - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7.35 % |
France Generics Market Intelligence Report
9
|
February 2006 |
£295 |
7.35 % |
Biomarkers
The Expanding Global Market
|
November 2007 |
£2960 |
7.35 % |
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry
|
April 2009 |
£6000 |
7.35 % |
Partneringreview 2006 – Deal Type
Volume 5
|
February 2006 |
£1395 |
7 % |
United Kingdom Healthcare IT Investment Opportunities
Analysis and Forecasts to 2015
|
March 2009 |
£1525 |
7 % |
Sunesis Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7 % |
Botanical and Plant-Derived Drugs
Global Markets
|
February 2009 |
£2960 |
7 % |
SuperGen, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7 % |
CuraGen Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7 % |
EntreMed, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7 % |
ADVENTRX Pharmaceuticals - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7 % |
Genomic Health, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7 % |
Drug Delivery Technology: Developing a New Generation of Vaccines
|
November 2007 |
£945 |
7 % |
Anadys Pharmaceuticals, Inc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7 % |
Hana Biosciences, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7 % |
Ariad Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7 % |
IDM Pharma, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7 % |
Forecast Insight: Opioids - Saturation limits the commercial potential of individual brands
Healthcare
|
March 2009 |
£8000 |
7 % |
Partneringreview 2006 – Therapy Area
Volume 2
|
February 2006 |
£1395 |
7 % |
Partneringreview 2006 - Company Deal Index
Volume 1
|
February 2006 |
£1395 |
7 % |
Pipeline Insight: Hepatitis C
Protease inhibitors to drive market expansion
|
June 2006 |
£6495 |
7 % |
SpectraScience, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7 % |
Global Protein Therapeutics Market, The
Market Dynamics and Pipeline Analysis
|
December 2006 |
£1830 |
7 % |
Market for Bioengineered Protein Drugs; The
|
January 2007 |
£2960 |
7 % |
Global Vaccine Market Outlook (2007-2010)
|
June 2007 |
£975 |
6.65 % |
Zila, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
6.65 % |
Averion International Corp. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
6.65 % |
Clinical Trials Business; The
|
August 2006 |
£2960 |
6.65 % |
Global Smoking Cessation Market Analysis & Forecasts
Preparing For The First Blockbuster
|
July 2007 |
£1499 |
6.65 % |
Exact Sciences Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
6.65 % |
Injectable Generic Drugs
Prospects & Opportunities to 2013
|
July 2008 |
£1295 |
6.65 % |
Quest Diagnostics Incorporated - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
6.65 % |
Emerging Opportunities in Cancer Nanomedicine
|
August 2006 |
£995 |
6.65 % |
Germany Healthcare IT Investment Opportunities
Analysis and Forecasts to 2015
|
March 2009 |
£1525 |
6.65 % |
Complete Guide to the Diagnostic Market 2007-2012
|
January 2007 |
£1600 |
6.3 % |
Mammography World Markets
|
October 2008 |
£2075 |
6.3 % |
U.S. Market for Gastrointestinal Pharmaceuticals
|
September 2005 |
£2960 |
6.3 % |
Siemens Medical Solutions Medical Equipment Company Share Analysis
|
September 2008 |
£610 |
6.3 % |
Drug Delivery Markets
Oral Delivery
|
January 2007 |
£1520 |
6.3 % |
Computed Tomography (CT) Systems Market Worldwide 2009
|
April 2009 |
£1520 |
6.3 % |
Stakeholder Opinions: Back Pain
Gain competitive edge by targeting subpopulations
|
March 2009 |
£2000 |
6.3 % |
In Vitro Diagnostic Companies Analysis
|
September 2007 |
£595 |
6.3 % |
Global Biotech Market Analysis and Forecasts, 2008-2023
|
August 2008 |
£1499 |
6.3 % |
U.S. Market for ENT, Bronchoscopy and Neuroendoscopy 2009
|
February 2009 |
£4575 |
6.3 % |
The Vaccines 2008
World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry
|
April 2008 |
£2500 |
6.3 % |
Commercializing Molecular Diagnostics:
Products, Services, Companies and Global Market
|
July 2008 |
£1585 |
6.3 % |
Healthcare in a Recession
(OTC, Generics, Out of Pocket Spending, Healthcare Legislation, Retail Clinics, Outsourcing and Other Topics)
|
March 2003 |
£1215 |
6.3 % |
Drug Treatments for Leading Endocrine and Metabolic Diseases
|
February 2007 |
£2960 |
5.95 % |
Who's Doing What in Molecular Diagnostics?
Kalorama / Emmes Survey of US Laboratories
|
February 2002 |
£3045 |
5.95 % |
Rx to OTC Switches 2009
|
April 2004 |
£2435 |
5.95 % |
DNA Sequencing and PCR Markets
|
July 2008 |
£2075 |
5.95 % |
Drug Delivery Technology: Revolutionizing CNS Therapies
|
December 2007 |
£945 |
5.95 % |
Indian Pharmaceutical Market, 2006-2011
|
June 2006 |
£1499 |
5.95 % |
Israel Healthcare IT Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1830 |
5.95 % |
Cell Therapy Markets
|
July 2007 |
£2075 |
5.6 % |
Japan Healthcare IT Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1830 |
5.6 % |
Urodynamics Equipment and Disposables Markets Worldwide
|
June 2007 |
£910 |
5.6 % |
Molecular Diagnostics Markets
|
September 2008 |
£2075 |
5.6 % |
RNAi
Technologies, Markets and Companies
|
May 2009 |
£1830 |
5.6 % |
Bausch & Lomb Incorporated Healthcare - Medical Equipment SWOT Report
|
August 2008 |
£76 |
5.6 % |
In Vitro Diagnostics Market Analysis 2009-2024
|
May 2009 |
£1499 |
5.6 % |
Top Ten Global In-Vitro Diagnostics Companies
Positioning, performance and SWOT analyses
|
March 2009 |
£2025 |
5.6 % |
Dental Market: Techniques, Equipment & Materials, the
|
December 2008 |
£2960 |
5.6 % |
Home Medical Testing Devices
|
January 2008 |
£1220 |
5.6 % |
Pfizer
Market Outlook for a Global Leader, 2008-2013
|
August 2008 |
£1499 |
5.6 % |
Plant-Derived Drugs: Products, Technology, Applications
|
June 2006 |
£2960 |
5.25 % |
Medical Nanotechnology Markets
|
September 2008 |
£2075 |
5.25 % |
United States Drug Delivery Devices Medical Equipment Industry Report
Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Infusion Systems, Inhalation Systems and Needle Free Injections Medical Equipment and Supplies
|
April 2008 |
£1830 |
5.25 % |
Medical Imaging Markets
|
December 2008 |
£2075 |
5.25 % |
Stakeholder Opinions
Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of Market Prospects for Biologics Expose An Opportunity for Cell and Gene Therapies
|
July 2008 |
£3800 |
5.25 % |
Outsourcing Clinical Trials
A Global Analytical Guide and Comparative Analysis of International Destinations, with Location Attractiveness Index
|
May 2007 |
£1830 |
5.25 % |
Clinical Nutrition Products: World Market, 2nd. Edition
|
August 2007 |
£2130 |
5.25 % |
Companion Biomarkers in Drug Development
|
April 2009 |
£2075 |
5.25 % |
Clinical Diagnostics in China
Market Sector Analyses and Participant Directory
|
January 2008 |
£6340 |
5.25 % |
Pharmacogenomics: New Technologies
In the Development of Personalized Therapies
|
August 2005 |
£2960 |
5.25 % |
Microarray Markets
|
September 2008 |
£1220 |
5.25 % |
Clinical Diagnostics in India
Market Sector Analyses and Participant Directory
|
December 2006 |
£3045 |
5.25 % |
Arthrocare Corporation Healthcare - Medical Equipment SWOT Report
|
August 2008 |
£76 |
5.25 % |
Orphan Drugs to 2008
Understanding regulation & market opportunity in Europe
|
January 2005 |
£995 |
4.9 % |
Nanotechnology in Health Care to 2009
|
May 2005 |
£2560 |
4.9 % |
Medical Imaging Markets, Volume V
Molecular Imaging
|
May 2007 |
£1825 |
4.9 % |
Russian Pharma Sector Analysis (2007)
|
August 2007 |
£670 |
4.9 % |
Nanotechnology in Health Care
|
February 2007 |
£2745 |
4.9 % |
Arthrocare Corporation Medical Equipment Company Share Analysis
|
September 2008 |
£610 |
4.9 % |
Laparoscopic Devices Market Research Report Worldwide
|
June 2009 |
£1215 |
4.9 % |
Physician Office Laboratory (POL) Testing Markets Worldwide
Status Quo and Future Trends
|
May 2007 |
£2135 |
4.9 % |
Prosthetics, Orthotics and Cosmetic Enhancement Products
|
October 2005 |
£2960 |
4.9 % |
Commercial and Pipeline Insight: Systemic antifungals
|
November 2007 |
£7600 |
4.9 % |
SNP Genotyping and Analysis Markets
|
June 2008 |
£2435 |
4.55 % |
Stem Cell Markets
|
October 2008 |
£2075 |
4.55 % |
The Market for In Vitro Toxicology Testing
|
March 2007 |
£2960 |
4.55 % |
Global Medical Markets for Nanoscale Materials and Devices
|
January 2008 |
£2960 |
4.55 % |
Spain Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1830 |
4.55 % |
Veterinary Health Markets
|
December 2008 |
£2075 |
4.55 % |
Nitric Oxide
Therapeutics, Markets and Companies
|
May 2009 |
£1710 |
4.55 % |
F. Hoffmann-La Roche Ltd. Medical Equipment Company Share Analysis
|
September 2008 |
£610 |
4.55 % |
Drug Delivery Series I-IV
|
April 2007 |
£4360 |
4.55 % |
China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1830 |
4.55 % |
Herbal Supplements, Prescription Drugs, Rx-to-OTC Products
A Comparison
|
October 2006 |
£2960 |
4.55 % |
Labeling and Linkage Agents for Immunoassays and Gene Probes
|
April 2006 |
£2960 |
4.2 % |
Medical Imaging: Reagents and Analysis Tools
|
December 2006 |
£2960 |
4.2 % |
Over-the-Counter Diagnostic Products World Markets
|
September 2006 |
£2075 |
4.2 % |
Terahertz Radiation Systems
Technologies and Global Markets
|
November 2008 |
£1985 |
4.2 % |
Australia Healthcare IT Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1830 |
4.2 % |
Mentor Medical Device Company Intelligence Report
|
July 2006 |
£395 |
4.2 % |
World Market for Molecular Diagnostics, The
|
January 2009 |
£2435 |
4.2 % |
United States Neurology Devices Medical Equipment Industry Report
Detailed Analysis of The Medical Equipment & Medical Devices Market Covering Csf Management, Interventional Neurology, Neurosurgical Products, Radiosurgery and Neurostimulation Devices, Equipment and Supplies
|
May 2008 |
£1830 |
4.2 % |
Opportunities in Digestive & Immunity Health: Consumer Attitudes & Behaviors
|
February 2009 |
£2110 |
4.2 % |
World Market for Prescription Generic Drugs
6th Edition
|
April 2008 |
£2435 |
4.2 % |
RNA Interference for Drug R&D
Applications, Alliances, Companies and WW Market to 2011
|
July 2007 |
£1585 |
3.85 % |
DNA Sequencing: Emerging Technologies and Applications
|
January 2008 |
£2960 |
3.85 % |
Nanomedicine 2006-2011
|
June 2006 |
£1499 |
3.85 % |
Pain Therapeutics
Drugs, Markets and Companies
|
May 2009 |
£1830 |
3.85 % |
Radiation-based Therapy and Therapeutic Imaging
|
May 2005 |
£2960 |
3.85 % |
The Worldwide Market for In Vitro Diagnostic Tests
6th Edition [with 2009 Economy Preface]
|
May 2008 |
£2435 |
3.85 % |
GE Healthcare Medical Device Company Intelligence Report
|
April 2009 |
£495 |
3.85 % |
Clinical Laboratory Testing Volume 2: Business Strategies
|
April 2009 |
£1220 |
3.85 % |
Direct-To-Consumer Genetic Testing
Business Prospects in the United States
|
March 2009 |
£2290 |
3.85 % |
Drug Delivery Systems
US Market Outlook, Advances for Pharma, Biotech & Medical Devices
|
September 2006 |
£1400 |
3.5 % |
The Pharmaceutical Market: India
|
February 2007 |
£595 |
3.5 % |
The Market for Minimally Invasive Medical Devices
|
March 2009 |
£2960 |
3.5 % |
Siemens Medical Solutions Medical Device Company Intelligence Report
|
February 2007 |
£395 |
3.15 % |
The U.S. Market for Ethical Nutrition in Healthcare
|
June 2007 |
£2960 |
3.15 % |
Protein Therapeutics Market; The
The Science and Business of a Growing Sector
|
June 2006 |
£2380 |
3.15 % |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
|
June 2007 |
£1999 |
3.15 % |
Three Alternative Scenarios Of The Future In Vitro Diagnostics Market 2007-2016
|
January 2008 |
£7200 |
3.15 % |
Global Medical Tourism
|
December 2008 |
£2075 |
2.8 % |
Point of Care Diagnostic Testing World Markets
|
September 2008 |
£2075 |
2.8 % |
Disposable Medical Supplies Markets
|
April 2009 |
£2075 |
2.8 % |
Organ Transplant Immunosuppressive Markets
|
January 2008 |
£2135 |
2.8 % |
Generic League
Market Analysis and Forecasts, 2007-2012, 2017 & 2022
|
February 2008 |
£1999 |
2.45 % |
Cell-Based Assays for Drug Discovery
|
January 2009 |
£2075 |
2.45 % |
DNA Diagnostics: Technologies and Global Markets
|
January 2008 |
£2960 |
2.45 % |
Live-Licensing & In-life Testing
R&D Processes and Regulation for New Drugs, 2008-2020
|
January 2008 |
£1499 |
2.1 % |
China Medical Device Industry Report, 2005-2006
|
May 2006 |
£1100 |
1.75 % |
